ELPIS II Null Result Exposes Endpoint Mismatch Risk; HLHS Path Requires FDA Lifeline

Longeveron's ELPIS II Trial Misses Primary Endpoint in HLHS

Longeveron announced topline results from its Phase 2b ELPIS II trial evaluating its investigational stem cell therapy, laromestrocel, for Hypoplastic Left Heart Syndrome (HLHS). The trial, involving 40 infants, did not meet its primary endpoint of improvement in right ventricular ejection fraction (RVEF) at Month 12, showing a least-squares mean difference of −0.7 percentage points (95% CI: −7.3 to 5.9; p=0.8336). However, exploratory analyses indicated potential positive trends, including fewer deaths (0 vs 1) and approximately 31% fewer Major Adverse Cardiovascular Events (MACE) in the laromestrocel arm, though not statistically significant. The drug maintained a favorable safety profile. Longeveron plans to discuss these results with the FDA and is exploring options to maximize shareholder value, including advancing laromestrocel in other indications like Aging-related Frailty.

• The ELPIS II Phase 2b trial, investigating laromestrocel in 40 infants with HLHS, failed to meet its primary efficacy endpoint. The primary endpoint, change from baseline in right ventricular ejection fraction (RVEF) at Month 12, showed a least-squares mean difference of −0.7 percentage points (95% CI: −7.3 to 5.9; p=0.8336) between treatment groups, indicating no statistically significant improvement. This outcome necessitates further discussion with the FDA regarding the HLHS development program.
• Despite the primary endpoint not being met, exploratory analyses revealed some potentially positive clinical trends. Over 12 months, there were no deaths in the laromestrocel arm compared to one in the control group. Long-term transplant-free survival showed one event in 17 laromestrocel patients versus two in 21 standard-of-care patients. Additionally, adjudicated Major Adverse Cardiovascular Events (MACE) were approximately 31% fewer in the laromestrocel arm (12 events vs. 19 events), although this difference was not statistically significant.
• Laromestrocel demonstrated a favorable safety and tolerability profile in ELPIS II, consistent with prior clinical trials across 644 treated patients, with no new safety signals identified. The company reported similar rates of treatment-emergent adverse events and serious adverse events between treatment and control groups. Longeveron plans to conduct additional analyses and engage with the U.S. FDA to discuss the complete dataset and determine potential next steps for the HLHS development program, as the FDA had previously expressed willingness to meet.
• In light of the ELPIS II results, Longeveron is initiating a review of all options to maximize shareholder value, including optimizing cost containment and potentially engaging an investment bank. The company also intends to pursue funding and revenue opportunities to advance laromestrocel in other promising indications, particularly in longevity and Aging-related Frailty, where Phase 2b results published in Cell Stem Cell showed improved physical condition and led to a $1 million XPRIZE Healthspan award.

ELPIS II: Unpacking Laromestrocel's Mixed Outcomes in HLHS

Recent clinical investigation into cell-based therapies for hypoplastic left heart syndrome (HLHS) has focused on autologous stem cell approaches targeting right ventricular (RV) dysfunction — a primary driver of morbidity and mortality in this population. Two studies stand out for their evaluation of safety, feasibility, and early efficacy signals.

• Phase 1 Trial — Autologous Umbilical Cord Blood-Derived Mononuclear Cells: This trial enrolled 10 infants with HLHS and delivered autologous umbilical cord blood-derived mononuclear cells via direct intramyocardial injection at the time of stage II palliation. Operative mortality was 0%, and the sole adverse event attributable to cell delivery was an injection site epicardial bleed requiring simple oversew. Over 6 months of follow-up, no significant safety concerns were identified. Secondary findings included preservation of baseline RV function throughout follow-up and normalized growth rates, supporting progression to a phase 2b trial.

• CHILD Study (Autologous Cardiac Stem Cell Injection in Patients with Hypoplastic Left Heart Syndrome) — Neonatal c-kit Cardiac-Derived Progenitor Cells (nCPCs): This Phase I/II trial investigates intramyocardial administration of autologous nCPCs in HLHS infants across 4 institutions, with a planned enrollment of 32 patients. Group A (Phase I, n = 10) assesses safety and feasibility using an open-label, multicenter design. Group B (Phase II, n = 22) employs a randomized, double-blinded, multicenter design to evaluate nCPC efficacy based on RV functional and structural characteristics. The rationale is supported by preclinical evidence of RV dysfunction improvement and the demonstrated superior efficacy of neonatal human-derived CPCs compared to adult human cardiac-derived CPCs.

Addressing the Persistent Unmet Need in Hypoplastic Left Heart Syndrome

Despite meaningful advances in surgical technique and perioperative care, staged palliation for Hypoplastic Left Heart Syndrome (HLHS) continues to carry substantial mortality and morbidity at every phase of the treatment pathway. Mortality following Stage I palliation varies from 10% up to 40% across institutions, and risks persist well beyond the initial hospitalization into the interstage period and beyond Glenn completion.

• Interstage mortality remains a significant burden. Among hospital survivors of neonatal palliation, 10% die before progressing to Glenn. Factors independently associated with interstage mortality include weight ≤2.5 kg (hazard ratio 2.4), premature birth ≤36 weeks (hazard ratio 2.0), genetic syndromes (hazard ratio 3.2), unplanned cardiac reoperation (hazard ratio 2.1), prolonged ICU stay >30 days (hazard ratio 2.5), and aortopulmonary shunt circulation after Norwood (hazard ratio 5.4).

• Tricuspid valve regurgitation compromises long-term outcomes. Moderate to severe tricuspid valve regurgitation is not uncommon in patients with HLHS undergoing staged reconstruction and can arise from abnormal valve morphology, incomplete leaflet coaptation, or aortic arch re-obstruction. Significant tricuspid regurgitation remains an obstacle to improving survival after the Norwood procedure and likely compromises functional health after the Fontan procedure.

• Fontan circulation imposes chronic multi-organ dysfunction. The Fontan physiology chronically increases systemic venous pressure, causing venous congestion and decreased cardiac output, which predisposes patients to progressive failure. Systemic complications include Fontan-associated liver disease (FALD), protein-losing enteropathy (PLE), plastic bronchitis (PB), renal impairment, arrhythmias, thromboembolic events, and endocrine and psychosocial burdens — all contributing to frequent hospitalizations and impaired quality of life.

• Neurodevelopmental impairment begins in utero and persists. Fetuses with single ventricle anatomy exhibit statistically significant disparity in brain composition compared with biventricular controls, despite similar total brain volumes. Postnatally, infants with a single ventricle demonstrate significantly low scores in language and gross motor skills at 3 years, and total brain volume remains persistently smaller in single ventricle children than in comparator congenital heart disease groups through 9 years of age, with total brain volume at 3 years serving as a strong predictor of total brain volume at 9 years.

• High-risk patient subgroups present particular operative challenges. Neonates with the most severe HLHS morphology — specifically mitro-aortic atresia — face the greatest operative risk; in one series employing a selective cerebro-myocardial perfusion beating-heart strategy, postoperative deaths occurred exclusively in this subgroup due to cardiac dysfunction and failure to wean from veno-arterial ECMO. Acute kidney injury requiring peritoneal dialysis was observed in 75% of patients in that same series, underscoring the extent of end-organ vulnerability even with innovative perfusion strategies.

Laromestrocel's Favorable Safety Profile and Broader Therapeutic Promise

In a randomized, double-blind, placebo-controlled, parallel-group phase 2a trial evaluating laromestrocel — a bone-marrow-derived, allogeneic mesenchymal stem-cell therapy — in mild Alzheimer's disease, the study met its primary endpoint of safety. The rate of treatment-emergent serious adverse events within 4 weeks of any infusion was comparable across all four groups: 0% (95% CI 0–26.5%) for placebo, 7.7% (95% CI 0.2–36%) for the 25 million cell single-dose group, 7.7% (95% CI 0.2–36%) for the 25 million cell four-dose group, and 9.1% (95% CI 0.2–41.3%) for the 100 million cell four-dose group. Notably, there were no reported infusion-related reactions, hypersensitivities, or amyloid-related imaging abnormalities across any treatment arm, supporting the tolerability of both single and multiple doses of laromestrocel.

Beyond the primary safety findings, laromestrocel demonstrated signals of clinical efficacy at 39 weeks. Compared to placebo, treatment groups showed improvement on a composite Alzheimer's disease score (secondary endpoint met: group 2 versus placebo change: 0.38; 95% CI −0.06–0.82), as well as on the Montreal Cognitive Assessment and the Alzheimer's Disease Cooperative Study Activities of Daily Living. Laromestrocel also slowed the decline of whole brain volume by 48.4% for all treatment groups combined (groups 2–4: P = 0.005; n = 32) and left hippocampal volume by 61.9% (groups 2–4, P = 0.021; n = 32), with a reduction in neuroinflammation as measured by diffusion tensor imaging. The change in bilateral hippocampal atrophy correlated with the change in mini-mental state exam scores (R = 0.41, P = 0.0075) across all study patients (N = 42).

The knowledge base does not have sufficient information on this aspect regarding laromestrocel's safety and tolerability data across any indications beyond mild Alzheimer's disease.

Laromestrocel's Path: From HLHS Disappointment to Frailty Promise

The recent announcement regarding laromestrocel's Phase 2b ELPIS II trial in Hypoplastic Left Heart Syndrome (HLHS) presents a complex picture for the investigational stem cell therapy. While the primary endpoint of improved right ventricular ejection fraction (RVEF) at Month 12 was not met, the data are not without potential silver linings. Exploratory analyses hinted at fewer Major Adverse Cardiovascular Events (MACE) and deaths in the treatment arm, alongside a maintained favorable safety profile, consistent with earlier Phase 1 findings that suggested safety and potential favorable effects on RV performance. This outcome underscores the inherent challenges in developing therapies for complex congenital heart diseases, where defining and achieving statistically significant primary endpoints can be particularly difficult.

However, the company's stated intention to explore options, including advancing laromestrocel in other indications, points to a strategic pivot. This move is strongly supported by existing evidence from a randomized Phase 2b dose-escalation trial in Aging-related Frailty, where laromestrocel infusion resulted in clinically meaningful, dose- and time-dependent increases in the 6-minute walk test (6MWT), a primary endpoint. The identification of soluble TIE2 as a potential biomarker in this population further strengthens the rationale for pursuing this indication. This diversification strategy leverages the established safety profile of allogeneic mesenchymal stem cells (MSCs) and shifts focus to an area with demonstrated efficacy signals, potentially maximizing shareholder value.

The path forward for laromestrocel in HLHS will require careful discussion with regulatory bodies, as the lack of primary endpoint success poses significant hurdles. For the frailty indication, the company must now translate promising Phase 2b data into a robust Phase 3 program, capitalizing on the identified biomarker to potentially optimize patient selection and trial design. This dual-track approach highlights both the scientific challenges and strategic opportunities inherent in advanced cell therapy development.